Home › Gilead Initiates Phase 3 Clinical Program For Tenofovir Alafenamide, A Novel Low-Dose Prodrug For The Treatment Of HIV
 

Keywords :   


Gilead Initiates Phase 3 Clinical Program For Tenofovir Alafenamide, A Novel Low-Dose Prodrug For The Treatment Of HIV

2013-01-24 09:30:00| drugdiscoveryonline News Articles

Gilead Sciences, Inc. recently announced the initiation of the first of two Phase 3 clinical trials (Study 104) evaluating a single tablet regimen containing tenofovir alafenamide (TAF) for the treatment of HIV-1 infection in treatment-naïve adults

Tags: the of program treatment

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
28.09Eastern North Pacific Tropical Weather Outlook
28.09Atlantic Tropical Weather Outlook
28.09Post-Tropical Cyclone Helene Public Advisory Number 21
28.09Tropical Storm Joyce Public Advisory Number 5
28.09Summary for Tropical Storm Joyce (AT1/AL112024)
28.09Post-Tropical Cyclone Helene Public Advisory Number 21
28.09Tropical Storm Joyce Forecast Discussion Number 5
28.09Tropical Storm Joyce Wind Speed Probabilities Number 5
More »